Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. Jul 2008;10(3):218-27. [Medline].

[Best Evidence] Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. Oct 2006;65(10):1312-24. [Medline].

Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.Arthritis Rheum. Apr 2010;62(4):1060-8. [Medline].

Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. Aug 2011;63(8):2226-37. [Medline].

FDA takes action to stop the marketing of unapproved injectable drugs containing colchicine. US Food and Drug Administration. Available at www.fda.gov/bbs/topics/news/2008/new01791.html. Accessed September 30, 2008.

[Guideline] Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. Feb 1991;18(2):264-9.[Medline].

Yu T. The efficacy of colchicine prophylaxis in articular gout--a reappraisal after 20 years

1  . . .13 14 15 16 17 18 19 20 21 . . .22